University of Virgina Health System Trials

University of Virgina Health System	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Kramer, Christopher

NCT02959047: A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Completed

Alirocumab, Praluent, Matching placebo

University of Virginia, Northwestern University

Peripheral Arterial Disease

05/23

MOST, NCT03735979: Multi-arm Optimization of Stroke Thrombolysis

Active, not recruiting

514

Argatroban, Eptifibatide, Placebo

Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS)

Acute Ischemic Stroke

12/23

04/25

FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Recruiting

860

Europe, Canada, Japan, US

Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo

Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)

Intracerebral Hemorrhage

01/28

NCT05036213: The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD

Recruiting

BEET IT - Concentrate Beet root juice, Dietary Nitrate supplementation (nitrate rich), BEET IT - Concentrate Beet root juice (nitrate depleted), Dietary Nitrate supplementation (nitrate depleted)

University of Virginia

Peripheral Arterial Disease, Peripheral Vascular Diseases

12/24

NCT02388685: Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3

Terminated

N/A

Exercise

University of Virginia

Peripheral Arterial Disease

06/20

11/23

HCMR, NCT01915615: - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

Active, not recruiting

N/A

2750

Europe, Canada, US

None - this is an observational study

University of Virginia, National Heart, Lung, and Blood Institute (NHLBI), Oxford University Hospitals NHS Trust

Hypertrophic Cardiomyopathy

06/25

Johnson, Lisa

PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting

680

Europe, US, RoW

Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG

Immunocore Ltd

Advanced Melanoma

10/27

NCT05023655: Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Recruiting

Tazemetostat, tazverik

Prisma Health-Upstate, Ipsen

Solid Tumor, ARID1A Gene Mutation

01/26

01/27

NCT02938793: Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Recruiting

150

Durvalumab, MEDI4736, Tremelimumab, CP-675,206

Prisma Health-Upstate, AstraZeneca, MedImmune LLC

Cancer, Rare Disease

02/26

06/27

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting

1/2

200

BDTX-1535 monotherapy

Black Diamond Therapeutics, Inc.

Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation

07/25

06/26

NCT05705505: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Recruiting

1/2

Narazaciclib, ON 123300, HX-301, Letrozole 2.5mg, Femara

Onconova Therapeutics, Inc.

Endometrioid Endometrial Cancer

01/26

02/26

MT-5111_001, NCT04029922: Study of MT-5111 in HER2-positive Solid Tumors

Terminated

US, RoW

MT-5111 (experimental study drug)

Molecular Templates, Inc.

HER2-positive Solid Cancers

02/23

04/23

NCT04739293: Study of ON 123300 in Patients With Advanced Cancer

Recruiting

ON123300, HX 301

Onconova Therapeutics, Inc.

Solid Tumors, Adult

10/24

RGX-202-001, NCT03597581: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

Recruiting

108

ompenaclid, RGX-202-01, FOLFIRI, Bevacizumab, FOLFOX regimen

Inspirna, Inc.

Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Gastric Cancer, Gastric Neoplasm, KRAS Mutation-Related Tumors, CRC, Colorectal Cancer Metastatic

12/24

INDP-D101, NCT05651022: DECOY20 Study in Patients with Advanced Solid Tumors

Recruiting

120

Decoy20

Indaptus Therapeutics, Inc, Translational Drug Development

Solid Tumor, Adult

06/27

09/27

MT-6402-001, NCT04795713: Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1

Terminated

MT-6402

Molecular Templates, Inc.

Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck

10/24

NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

171

Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor

Kura Oncology, Inc.

AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type

08/26

08/27

NCT05923749: A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Recruiting

N/A

178

Europe, US

Biatain Ag, Cutimed Siltec Sorbact

Coloplast A/S

Wound Heal

10/25

Abdel-Rahman, Emaad M

NCT05828823: Incremental Hemodialysis: The TwoPlus Trial

Recruiting

N/A

350

Hemodialysis twice weekly, Hemodialysis thrice weekly

Wake Forest University Health Sciences, Patient-Centered Outcomes Research Institute

End-Stage Kidney Disease

09/27

03/28

Adelaja, Olusegun

ASP-1929-301, NCT03769506 / 2018-002513-36: ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Active, not recruiting

135

Japan, US, RoW

ASP-1929 Photoimmunotherapy, Physician's Choice SOC

Rakuten Medical, Inc.

Head and Neck Cancer

12/25

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

Mann, Kirsten

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

Frias, Diana

BA3021-002, NCT05271604: A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting

290

Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab, Erbitux

BioAtla, Inc.

Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck

12/26

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

Hapanowicz, Olivia

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting

550

Europe, US

Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1

Agenus Inc.

Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites